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Abstract
Purpose of Review We reviewed the HIVand opioid literature relevant to harm reduction strategies for those with criminal justice 
experience.
Recent Findings Opioid use in the United States has risen at an alarming rate recently. This has led to increased numbers of 
people who inject drugs, placing new populations at risk for HIV, including those who have criminal justice experience. In recent 
years, there has been a gradual decrease in the number of individuals under the supervision of the criminal justice system. 
However, concurrently, there has been a rise in the number of individuals incarcerated in jails in rural counties that are at the 
center of the current opioid epidemic.
Summary We provide a number of harm reduction strategies that could be implemented in correctional settings such as access 
and linkage to medication-assisted treatment, connection to syringe exchange programs and safe injection facilities (where 
available), and the repackaging of pre-exposure prophylaxis as a harm reduction tool.
Keywords Harm reduction . HIV . Opioid use . Criminal justice experience . Safe injection facilities . Syringe exchange programs
Introduction
The United States (US) criminal justice (CJ) system is the
largest in the world, with a greater number of individuals
incarcerated or under surveillance than any other nation [1].
The CJ system includes prisons that, in general, house indi-
viduals who have sentences that are greater than one year in
length; jails that include pre-trial detainees or individuals who
are typically serving sentences less than one year in length;
and community supervision which includes people who are on
probation or parole. A little over 6.7 million individuals or one
in 37 adults was involved in the criminal justice system at
year-end 2015 [1]. In recent years, there has been a gradual
decrease in the number of individuals involved in the CJ sys-
tem. However, concurrently, there has been a rise in the num-
ber of individuals incarcerated in jails in rural counties that are
at the center of the current opioid epidemic [2].
Opioid use in the US has risen at an alarming rate in
recent years. This epidemic of opioid misuse and abuse has
led to increased numbers of people who inject drugs
(PWID), placing new populations at increased risk for
HIV [3]. Average rates of heroin use increased from 1.6
per 1000 persons over the age of 12 in 2002 to 2004 to
2.6 in 2011 to 2013 [4]. In addition, this increase in heroin
use is associated with a corresponding rise in opioid-related
overdose deaths. Those who have CJ experience have a
higher incidence of both injection drug use (IDU) and
HIV. Individuals who are CJ involved have a rate of HIV
that is three times higher than the general population and
more than half of all people who are incarcerated meet the
diagnostic criteria for substance use disorder [5, 6]. This is,
due, in large part, to the fact that 13% of all arrests are due
to drug-related crime.
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The number of individuals with opioid use disorder (OUD)
is also exaggerated among those who are incarcerated [6]. Just
over 23% of state prisoners report ever using heroin or other
opiates, and 13% report regular use prior to incarceration [6].
In addition, people who have recently been incarcerated are at
extreme risk of overdose during community re-entry [7, 8]. A
recent study investigating all causes of mortality of people
who were formerly incarcerated in Washington state found
that overdose was the number one cause of death [8].
After release, individuals are also at increased risk of HIV
transmission and contraction, as many HIV-negative individ-
uals return to substance use in the community [9]. Research
has shown that among people who inject drugs, incarceration
impacts post-release HIV risk behaviors, including the sharing
of used needles [10]. For those who are HIV positive, incar-
ceration can result in HIV treatment disruption and non-
adherence to antiretroviral medications [11–13]. In fact, a re-
cent systematic review of HIV care continuum among those
with criminal justice experience demonstrated that rates of
viral suppression are even worse post-incarceration than be-
fore arrest [14].
However, jails and prisons have been slow to embrace
harm reduction strategies. The remainder of this paper will,
thus, focus on harm reduction techniques that can be deployed
in CJ settings to lessen the risk of HIV transmission and con-
traction targeted toward opioid users.
Harm Reduction Strategies for Opioid Users
with Current or Recent Incarceration
Much of the HIV harm reduction efforts among people who
inject drugs have focused primarily on provision of and link-
age to medication-assisted treatment (MAT), syringe ex-
change programs (SEPs) and related community services that
often include overdose prevention, and, in a more limited
capacity (in terms of geographic distribution), safe injection
facilities (SIFs). In addition, herein, we propose including pre-
exposure prophylaxis (PrEP) as a tool of harm reduction
among injection drug users.
Screening for Opioid Use Disorder and Risky
Injecting Behaviors
Screening and assessment tools have been developed to spe-
cifically identify those who have OUD in correctional set-
tings. This is a necessary and crucial step in addressing
OUD and subsequent HIV risk among those who are incarcer-
ated. However, few estimates of OUD disorder among those
involved in the CJ system exist mainly due to the fact that
screening for OUD is not a routine practice in most correc-
tional facilities. We recommend the inclusion of an OUD
screening tool such as the Rapid Opioid Dependence Screen
[15] or the Texas Christian University (TCU) drug screen-
opioid supplement [16] be used as a part of the intake process
in concert with mandated screening tools and HIV risk
assessments.
Medication-Assisted Treatment as HIV
Prevention
MAT has been extensively studied over the past four decades
as an effective treatment of OUD. Overall, MAT has been
shown to reduce drug use, re-incarceration, and overdose;
and increase continuous engagement in long-term treatment
among CJ-involved individuals [17–22]. Currently, there are
three medications approved by the US Food and Drug
Administration (FDA) to treat OUD: the opioid agonist meth-
adone, the opioid partial agonist buprenorphine, and the opi-
oid antagonist naltrexone, which has also been developed in a
depot, delayed release formulation for intramuscular injection.
MAT should be deployed in concert with HIV prevention
and treatment adherence strategies as recent research has dem-
onstrated that MAT, when delivered with HIV interventions,
has been shown to be most effective. For instance, for both
criminal justice- and non-criminal justice-involved popula-
tions, naltrexone not only effectively lowers rates of opioid
use and heavy alcohol consumption but also improves rates of
ART adherence in the community [23–29]. Despite the effec-
tiveness of MAT in treating OUD both during incarceration
and post-release, most correctional facilities in the US still do
not provide access to these medications.We recommend more




One of the HIV prevention strategies that could be combined
with MAT programs is pre-exposure prophylaxis (PrEP).
PrEP is a once daily medication (emtricitabine/tenofovir
disoproxil fumurate FTC/TDF) that has demonstrated efficacy
in preventing HIVamong at risk groups including PWID [30,
31]. In a randomized, double-blind, placebo-controlled trial
that included 17 drug treatment clinics in Bangkok,
Thailand, there was a 48.9% reduction in HIV incidence with
use of PrEP [31]. However, while PrEP has demonstrated
efficacy among PWID, in general, less is known about barriers
and facilitators of PrEP uptake and adherence among PWID
who have been recently incarcerated. Additionally, important
opportunities exist to gauge the possible “de-medicalization of
PrEP” to increase and ease access to this prevention method
and branding of PrEP, similar to syringe exchange, as a harm
reduction tool. This follows the Centers for Disease Control
and Prevention’s recommendations that PrEP be provided to
PWID as part of a comprehensive package of prevention ser-
vices [32]. Best practices for PrEP provision or linkage for
PWID should be investigated, but could take one of the fol-
lowing forms: (1) providing a PrEP prescription just prior to
discharge with linkage to a community PrEP provider, (2)
solely linking to a PrEP provider during discharge planning
[33].
Syringe Exchange Program Linkage
One of the pillars of harm reduction has been SEPs
which can be important portals to accessing services
for PWID, including overdose prevention assistance.
SEPs provide a wide variety of services including con-
dom distribution, referrals for substance use treatment,
HIV and hepatitis C virus counseling and testing, and
overdose training and prevention [34]. A large body of
evidence has clearly demonstrated that SEPs substantial-
ly reduce the risk for HIV transmission among PWID
[34]. While few studies have explicitly looked at the
subset of PWID who report criminal justice involve-
ment, SEPs can provide a range of important services
to individuals with OUD upon release from incarcera-
tion or who are on community supervision. Linkage
efforts could include access to an educational program
that introduces the concept of harm reduction and sy-
ringe exchange. During this program, individuals could
be enrolled in syringe exchange making easier their
ability to access clean needles immediately upon re-
lease. This is the model that the North Carolina Harm
Reduction Coalition is using in jails and prisons across
the state of North Carolina (see: www.nchrc.org).
Access to Safe Injection Facilities
Another important harm reduction strategy that has been
gaining increasing attention in recent years is safe injection
facilities (SIFs). These facilities provide PWID with sterile
injecting equipment and a safe space in which to inject under
the supervision of nurses and/or other healthcare personnel.
SIFs have been well studied and have been shown to reduce
overdose mortality [35] and injection-related injuries [35–37].
Importantly, these facilities have not been associated with in-
creases in the number of PWID [37], increased rates of relapse
[38], increases in publicly discarded injection equipment [39],
or increases in drug-related crime [40]. In addition, SIFs have
been shown to increase utilization of detox services [40, 41]
and substance use treatment [41–43].
Conclusion
As the number of opioid users in the US continues to rise,
multipronged harm reduction strategies must be deployed
with diverse groups of people at risk. Individuals who have
current or recent CJ involvement are a key population group
that is at increased risk of HIV transmission and infection.
To lessen this risk, we suggest expansion of MAT programs
in correctional settings that are implemented in concert with
HIV prevention efforts. In addition, opioid users involved in
the CJ system should be linked to SIFs and SEPs prior to
release. Finally, PrEP should be offered as a tool of harm
reduction alongside syringe exchange, MAT, and SIF
linkage.
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